Sign In
Buy ALXO
$1.67
-0.110 (-6.18%)
At Close: Jun 03, 2026
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
04:30pm, Tuesday, 05'th Mar 2024
- Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation
7 Small-Cap Stocks That Wall Street Loves for Good Reason
04:21pm, Friday, 22'nd Dec 2023
As we head into 2024, it's common for investors to look back on 2023. Much of this year had investors in a defensive posture.
ALX Oncology shares jump 9% after Jefferies upgrade
08:30am, Friday, 08'th Dec 2023
ALX Oncology Holdings Inc. shares ALXO, +9.73% climbed 9% premarket on Friday after Jefferies analysts upgraded the stock to buy, from hold. The stock is “very cheap,” the analysts wrote, given th
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
04:05pm, Monday, 13'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies tha
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
04:05pm, Tuesday, 10'th Oct 2023
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies tha
ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept
12:38am, Monday, 09'th Oct 2023
ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastroesophageal junction cancer. Final results from the ASPEN-06 study are exp
ALX Oncology Announces Pricing of Public Offering
08:00am, Thursday, 05'th Oct 2023
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies tha
ALX Oncology Announces Proposed Public Offering
04:10pm, Wednesday, 04'th Oct 2023
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies tha
ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data
12:46pm, Wednesday, 04'th Oct 2023
Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.
Why ALX Oncology Stock Is Skyrocketing Today
11:15am, Tuesday, 03'rd Oct 2023
ALX Oncology reported positive interim results from a phase 2 study of a combo drug featuring evorpacept. Evorpacept showed great potential in treating gastric/gastroesophageal junction cancer.
ALX Oncology stock doubles on early data from phase II cancer trial
08:47am, Tuesday, 03'rd Oct 2023
ALX Oncology Holdings Inc saw its stock value double in pre-market trading on the heels of promising interim data from a phase II study assessing the potential of its lead asset in cancer of the sto
-- Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies tha
ALX Oncology Announces September Investor Conference Participation
07:00am, Thursday, 31'st Aug 2023
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block
ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
11:31am, Thursday, 10'th Aug 2023
ALX Oncology Holdings Inc. (ALXO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisio
